Guided Therapeutics (GTHP) Net Cash Flow Growth (3y) (2014 - 2025)
Guided Therapeutics (GTHP) Net Cash Flow Growth (3y) (2014 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.94 Bn | 176.64 Bn | 6.27 Bn | -32.51% |
| 2 | Stryker | 128.78 Bn | 125.90 Bn | 3.81 Bn | -87.87% |
| 3 | Medtronic | 109.01 Bn | 99.79 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 68.59 Bn | 67.13 Bn | 3.61 Bn | -11.49% |
| 5 | Edwards Lifesciences | 47.66 Bn | 43.99 Bn | 1.29 Bn | -87.88% |
| 6 | GE HealthCare Technologies | 28.36 Bn | 26.07 Bn | 1.98 Bn | -65.12% |
| 7 | Dexcom | 28.30 Bn | 27.18 Bn | 750.30 Mn | 129.29% |
| 8 | Smith & Nephew | 26.93 Bn | 26.36 Bn | - | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.33 Bn | 2.07 Bn | -48.90% |
| 10 | Guided Therapeutics | 20.39 Mn | 20.32 Mn | 458,000.00 | 60.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 60.31% |
| Sep 30, 2025 | -26.88% |
| Jun 30, 2025 | 31.37% |
| Mar 31, 2025 | -74.67% |
| Dec 31, 2024 | 23.90% |
| Sep 30, 2024 | 40.32% |
| Jun 30, 2024 | 19.43% |
| Mar 31, 2024 | -28.81% |
| Dec 31, 2023 | 29.47% |
| Sep 30, 2023 | -50.76% |
| Jun 30, 2023 | -38.29% |
| Mar 31, 2023 | 18.46% |
| Dec 31, 2022 | -34.39% |
| Jun 30, 2022 | -252.14% |
| Mar 31, 2022 | 139.09% |
| Dec 31, 2021 | 51.21% |
| Sep 30, 2021 | -147.37% |
| Jun 30, 2021 | -110.19% |
| Mar 31, 2021 | 142.16% |
| Dec 31, 2020 | -76.15% |